Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
First Claim
Patent Images
1. A tablet for oral administration comprising:
- a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound
1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;
b. a filler;
c. a disintegrant;
d. a surfactant;
e. a lubricant; and
f. a binder which is polyvinylpyrrolidone.
2 Assignments
0 Petitions
Accused Products
Abstract
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
485 Citations
22 Claims
-
1. A tablet for oral administration comprising:
-
a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound
1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;b. a filler; c. a disintegrant; d. a surfactant; e. a lubricant; and f. a binder which is polyvinylpyrrolidone. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
2. A tablet for oral administration comprising:
-
a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound
1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;b. a filler; c. a disintegrant; d. a surfactant which is sodium lauryl sulfate and is present in an amount of 0.3 wt % to 2 wt % by weight of the tablet; e. a lubricant; and f. a binder.
-
-
3. A tablet for oral administration comprising:
-
a. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound
1) Form I wherein the Compound 1 Form I is present in an amount ranging from 25 mg to 250 mg;b. a filler; c. a disintegrant; d. a surfactant; e. a lubricant; and f. a binder; wherein Compound 1 Form I is present in an amount of 30 wt % to 70 wt % by weight of the tablet.
-
Specification